Novel SRC kinase blocker to slow osteoarthritis and joint pain
Official title: Pre-clinical development of a novel allosteric inhibitor of SRC kinase for spontaneous multi-joint osteoarthritis (OA) and OA-associated chronic pain
Funded at Reparris, INC. · NIH-11311650 · Data updated 2026-11-12
A new drug candidate that blocks a specific SRC kinase interaction is being tested to slow osteoarthritis progression and reduce joint pain.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Reparris, INC. NIH-funded |
| Lab location | 1 site (Lancaster, United States) |
| Project start | September 1, 2026 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $301,567 |
| NIH project number | 1R44AR086030-01A1 |
| Project ID | NIH-11311650 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with osteoarthritis or chronic OA-related pain in the joints, particularly those with inflammation and early-stage disease.
✕Less likely to help
Patients with advanced OA or non-joint pain conditions may not benefit from this preclinical program.
What this research studies
This funded project aims to develop and test a first-in-class treatment for osteoarthritis that targets SRC kinase recruitment rather than blocking the enzyme’s activity directly. Researchers will study the safety and effectiveness of the oral or injectable SRi compound in preclinical models and small-scale exploratory studies. The goal is to show that this SRi can reduce joint damage, inflammation, and pain while avoiding common side effects seen with other SRC inhibitors. If successful, the work could lay the groundwork for future tests in people with OA.
Why it matters
Potential benefit: If successful, the SRi could become a disease-modifying option for OA, potentially slowing joint damage and easing pain.
How similar studies have gone: Preclinical studies in mice have shown anti-arthritic and analgesic effects with SRC pathway targeting using SRi-like compounds.
Where this research is happening
-
Reparris, INC.
Lancaster, United States Active
Researchers
- Principal investigator: Shkhyan, Ruzanna — Reparris, INC.
- Study coordinator: Shkhyan, Ruzanna
Related research
Other NIH-funded projects on the same topics.
-
Targeted OA treatment at disease sites using a prodrug that releases an antioxidant at the pain-affected joint
A new prodrug approach delivers an antioxidant and anti-inflammatory drug directly to osteoarthritis-affected joints to reduce pain and damage with fewer side effects.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Motor cortex tricks to ease chronic pain
A study in rodents and people tests whether non-invasive brain stimulation of the motor cortex can reduce chronic pain and how best to target it.
-
Human pain center study to map normal and migraine-trigeminal neurons
A large NIH-funded project will map and study the human trigeminal neurons involved in migraines to understand what changes in these cells during headache conditions.
-
Understanding human pain neurons to improve migraine care
Researchers are studying human pain-sensing neurons to uncover what makes migraine start and persist, with the goal of better treatments for people who experience migraines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.